
    
      This is a randomized phase 2 trial of maintenance etoposide versus observation following
      HDCT+PBSCT for relapsed GCT. Patients who completed HDCT+PBSCT within the past 16 weeks will
      enroll and randomize in 1:1 fashion to maintenance daily oral etoposide 50mg/m2 vs.
      observation only.
    
  